AlphAIalphai — Financial news for AI agents
GuruFocusMAY 223 min read$ATRC

Insider Sell Alert: Karen Prange Sells 3,000 Shares of AtriCure Inc (ATRC)

Karen Prange, a Director at AtriCure Inc (ATRC), sold 3,000 shares of the company on May 20, 2026, reducing her holdings to 26,373 shares. This transaction follows a pattern of 12 insider sells and no insider buys for AtriCure over the past year. The stock is currently priced at $28.65, giving it a GuruFocus Value of $39.37, indicating it is modestly undervalued with a price-to-GF-Value ratio of 0.73.

Original reporting
GuruFocus · GuruFocus News
Published May 22, 2026, 3:25 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 22, 2026, 4:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Insider Sell Alert: Karen Prange Sells 3,000 Shares of AtriCure Inc (ATRC) — source image
Source · GuruFocus
Decision brief

The 30-second read

$ATRCBearishMed
01

Why it matters

The consistent insider selling could pressure the stock price downward, especially if accompanied by negative technical signals.

02

Market read

The news is moderately relevant for traders focusing on biotech and medical device sectors, especially those with short-term trading strategies.

03

What to watch

No recent positive catalysts; technical indicators are neutral to bearish; broader market conditions may influence stock movement

Timing: short-term (next 1-4 weeks)

Background

AtriCure Inc specializes in medical devices for atrial fibrillation and other cardiac procedures. Insider sales have been ongoing, with no recent insider purchases, suggesting cautious management outlook.

Company-level read

Ticker impact

$ATRCBearishMedium confidence
Context

Insider selling activity and bearish sentiment

Expected impact

Potential short-term decline of 5-10%

Evidence & confidence

Multiple insider sales over the past year and a bearish sentiment score support a cautious outlook. However, the stock remains undervalued, which could mitigate downside risk.

Market effects

Sector

The life sciences sector may experience slight negative sentiment due to insider selling in a key company

Regional

Limited regional impact, primarily affecting US-based investors

Global

Minimal

Counterpoint

What could challenge this read

Insider sales might be for personal liquidity needs and not indicative of company prospects; undervaluation could lead to future gains

Key entities

  • Insider
    Karen Prange

    Director at AtriCure Inc who sold 3,000 shares.

  • Company
    AtriCure Inc

    Medical device company specializing in atrial fibrillation treatment.

Read at source← All news

Related articles

JUL 23
$ATRCHigh

AtriCure, Inc. (ATRC): Results of Operations and Financial Condition

AtriCure, Inc. (ATRC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-7232026.htm EX-99.1 Document Exhibit 99.1 For immediate release July 23, 2026 AtriCure Reports Second Quarter 2026 Financial Results • Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year • Second Quarter 2026 profitabi

SEC EDGAR 8-K3 min
AUG 8
$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).

fool.com6 min
AUG 8
$SUNEMedAI 8/10

Pentagon to invest $400m in Australian rare earth mine

Sunrise Energy Metals said the US Pentagon will provide a conditional $400 million loan commitment to develop Syerston, a proposed scandium mine in Fifield, NSW. The project targets Western supply of scandium used in defence and other sectors amid China’s export restrictions. Sunrise also said it has a deal with Lockheed Martin for 25% of output for five years.

bssnews.net4 min
AUG 8
$WTRGMed

Trump administration to invest $3 billion in minerals projects to boost US defence supply chains

President Trump said the US will invest $3 billion in critical minerals and battery projects to expand domestic supply chains for national security. He announced Defence Department Office of Strategic Capital conditional loans totaling $1.4B to Sila Nanotechnologies, $400M to Sunrise Energy Metals, and $150M to Niron Magnetics, plus $58M Export-Import Bank loans. The plan also includes $100M in mining-school grants and $80M for three schools.

tribune.com.pk6 min